Vitamin PPI supplements for ectopic calcification in PXE
Part of Blood & lymphatic, Genetic & congenital, Heart & circulation, Skin clinical trials.
This trial studies whether taking PPI-type supplements can slow or reduce unwanted calcification in people with PXE. It’s meant to help manage disease changes caused by abnormal calcium deposits, based on your medical testing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 64 years old
- Your PXE diagnosis is confirmed by both genetics (genotype) and symptoms (phenotype)
- If you can become pregnant, you must use reliable birth control during the entire study
- You can give informed consent and can join without another conflicting drug study
- You must not have significant kidney problems (kidney clearance under 30 mL/min/1.73 m²)
- You must not have low calcium or low vitamin D that hasn’t been corrected yet
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a compound that affects certain chemicals in your body (purines) to see if it helps people with pseudoxanthoma elasticum (PXE), a rare genetic condition affecting skin, eyes, and blood vessels.
This study looks at whether a new way of organizing care helps patients with pseudoxanthoma elasticum (PXE). It also asks some patients about their experience with the new care setup.
This study looks at blood flow in a layer of the eye called the choriocapillaris in people with pseudoxanthoma elasticum (PXE). It compares these findings with healthy volunteers to understand eye changes before they become severe.
This Phase 3 study tests a medicine to help prevent abnormal calcium (called ectopic mineralization) from building up in people with pseudoxanthoma elasticum (PXE). It aims to slow or reduce new damage over time.
This study uses special eye imaging to track changes caused by PXE, a rare genetic condition. It may help researchers understand how PXE affects the eyes over time.
This study tests a new drug called EPN-701 for calciphylaxis, a serious condition where calcium deposits damage blood vessels and skin, causing painful sores. If you have this condition and are on regular dialysis, this trial may help reduce your pain and heal your wounds.
Hear when a new Pseudoxanthoma Elasticum trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.